{"protocolSection": {"identificationModule": {"nctId": "NCT01199289", "orgStudyIdInfo": {"id": "20090203"}, "organization": {"fullName": "Amgen", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma"}, "statusModule": {"statusVerifiedDate": "2021-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-10-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-12-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-05", "studyFirstSubmitQcDate": "2010-09-09", "studyFirstPostDateStruct": {"date": "2010-09-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-10-29", "resultsFirstSubmitQcDate": "2021-10-29", "resultsFirstPostDateStruct": {"date": "2021-11-26", "type": "ACTUAL"}, "dispFirstSubmitDate": "2015-04-28", "dispFirstSubmitQcDate": "2015-04-28", "dispFirstPostDateStruct": {"date": "2015-05-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-10-29", "lastUpdatePostDateStruct": {"date": "2021-11-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amgen", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine if AMG 827 is effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Amgen", "chronic inflammatory disease", "wheezing"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 315, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "interventionNames": ["Drug: Placebo"]}, {"label": "AMG 827 140 mg", "type": "EXPERIMENTAL", "description": "Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "interventionNames": ["Drug: AMG 827"]}, {"label": "AMG 827 210 mg", "type": "EXPERIMENTAL", "description": "Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "interventionNames": ["Drug: AMG 827"]}, {"label": "AMG 827 280 mg", "type": "EXPERIMENTAL", "description": "Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "interventionNames": ["Drug: AMG 827"]}], "interventions": [{"type": "DRUG", "name": "AMG 827", "description": "SC injection.", "armGroupLabels": ["AMG 827 140 mg", "AMG 827 210 mg", "AMG 827 280 mg"]}, {"type": "DRUG", "name": "Placebo", "description": "SC injection.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12", "description": "The ACQ is an instrument used in clinical research and practice to evaluate asthma control/impairment.\n\nIt is a validated composite score that assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon awakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and forced expiratory volume in 1 second (FEV1).\n\nThe response options for all these questions range from zero (no impairment/limitation) to six (total impairment/limitation) scale. The total score is obtained by adding the value from each question and dividing by the number of questions. Higher scores indicates worsening of condition and a negative change from baseline indicates improvement.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. FEV1 was performed both pre and post-administration of bronchodilator treatment at Baseline and Week 12.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR) to Week 12", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in the Frequency of Rescue Short Acting \u03b2-Agonist (SABA) Use to Week 12", "description": "Participants recorded SABA use for 1 week prior to randomization (baseline) and the average number of days recorded was subtracted from average days of SABA use across 12 week intervention period.", "timeFrame": "Baseline to Week 12"}, {"measure": "Change From Baseline in Daily Asthma Symptom Score to Week 12", "description": "Participants recorded their daily asthma symptoms in their electronic diaries (Ediary). It included 7 questions: frequency of night time awakening, time awake at night, wheezing, shortness of breath, cough, chest tightness and activity limitation.\n\nDaily asthma symptoms score is the sum of 7 individual scores (with the total score ranging from 0-21).\n\nHigher scores indicates worsening of condition and a negative change from baseline indicates improvement.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12", "description": "The AQLQ is the most commonly used asthma specific instrument and includes evaluations of both symptom and quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms (Mitchell EA et al, 1997, Juniper et al, 1994, Christie MJ et al, 1993, Juniper et al, 1993).\n\nParticipants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score = mean of the responses to the 32 questions.\n\nHigher scores indicate \"better quality of life\" and a positive change from baseline indicates improved symptoms.", "timeFrame": "Baseline and Week 12"}, {"measure": "Proportion of Asthma Symptom-free Days", "description": "Asthma symptom-free days were defined as a participant having a score of zero in their daily asthma symptom score. Asthma symptom-free days without SABA use were defined as a participant having a score of zero in their daily asthma symptom score and no SABA use.\n\nThe proportion of asthma symptom-free days was calculated as the number of asthma symptom-free days over the number of days in the double-blind treatment period (12 weeks).", "timeFrame": "Up to Week 12"}, {"measure": "Time to Maximum Observed Concentration (Tmax) of AMG 827 at Week 8 to 10", "timeFrame": "Week 8 (days 60 and 64), and pre-dose on Week 10"}, {"measure": "Maximum Observed Concentration (Cmax) of AMG 827 at Week 8 to 10", "timeFrame": "Week 8 (days 60 and 64), and pre-dose on Week 10"}, {"measure": "Area Under the Concentration-time Curve During the Dosing Interval (AUCtau) of AMG 827 at Week 8 to 10", "timeFrame": "Week 8 (days 60 and 64), and pre-dose on Week 10"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men or women 18 to 65 years of age\n* Percent of predicted FEV1 \u2265 50% and \u2264 80%\n* At least 12% reversibility over pre-bronchodilator FEV1\n* Inhaled corticosteroid (ICS) \u2265 200 and \u2264 1000 \u00b5g/day fluticasone powder or equivalent\n* Ongoing asthma symptoms with ACQ composite score \u2265 1.5 points\n\nExclusion Criteria:\n\n* Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit\n* History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma\n* Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Encinitas", "state": "California", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Research Site", "city": "Huntington Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Stockbridge", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "North Dartmouth", "state": "Massachusetts", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Bozeman", "state": "Montana", "country": "United States", "geoPoint": {"lat": 45.67965, "lon": -111.03856}}, {"facility": "Research Site", "city": "Bellevue", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Research Site", "city": "Skillman", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Research Site", "city": "Rockville Centre", "state": "New York", "country": "United States", "geoPoint": {"lat": 40.65871, "lon": -73.64124}}, {"facility": "Research Site", "city": "High Point", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Lake Oswego", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Feldbach", "country": "Austria", "geoPoint": {"lat": 46.95306, "lon": 15.88833}}, {"facility": "Research Site", "city": "Hallein", "country": "Austria", "geoPoint": {"lat": 47.68333, "lon": 13.1}}, {"facility": "Research Site", "city": "Wien", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Research Site", "city": "Bruxelles", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Research Site", "city": "Leuven", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Research Site", "city": "Liege", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Helsinki", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Research Site", "city": "Jyv\u00e4skyl\u00e4", "country": "Finland", "geoPoint": {"lat": 62.24147, "lon": 25.72088}}, {"facility": "Research Site", "city": "Turku", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"facility": "Research Site", "city": "Edeleny", "country": "Hungary", "geoPoint": {"lat": 48.3, "lon": 20.73333}}, {"facility": "Research Site", "city": "Matrahaza", "country": "Hungary", "geoPoint": {"lat": 47.87124, "lon": 19.97981}}, {"facility": "Research Site", "city": "Tatabanya", "country": "Hungary", "geoPoint": {"lat": 47.58494, "lon": 18.39325}}, {"facility": "Research Site", "city": "Torokbalint", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Research Site", "city": "Zalaegerszeg - Pozva", "country": "Hungary"}, {"facility": "Research Site", "city": "Bucheon-si", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Rotterdam", "country": "Netherlands", "geoPoint": {"lat": 51.9225, "lon": 4.47917}}, {"facility": "Research Site", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Chodziez", "country": "Poland", "geoPoint": {"lat": 52.99505, "lon": 16.9198}}, {"facility": "Research Site", "city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Saint Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}]}, "referencesModule": {"references": [{"pmid": "24200404", "type": "BACKGROUND", "citation": "Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013 Dec 1;188(11):1294-302. doi: 10.1164/rccm.201212-2318OC."}], "seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A washout period for specific asthma medications was conducted after informed consent and prior to run-in period. After completing screening and meeting all eligibility criteria, all eligible participants underwent run-in visits for 4 weeks prior to randomization.", "recruitmentDetails": "This study was conducted at 61 centers in Austria, Belgium, Canada, Finland, Hungary, Netherlands, Poland, Russia, South Korea, and the United States; 47 of these sites enrolled participants from 04 October 2010 to 21 December 2011. 315 participants were enrolled, but 10 participants from 1 site were excluded from all analyses due to major issues of Good Clinical Practice (GCP) compliance and are not included in the participant flow.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "FG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "FG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "FG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "75"}, {"groupId": "FG002", "numSubjects": "76"}, {"groupId": "FG003", "numSubjects": "77"}]}, {"type": "Participants Who Received Study Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "76"}, {"groupId": "FG001", "numSubjects": "74"}, {"groupId": "FG002", "numSubjects": "76"}, {"groupId": "FG003", "numSubjects": "76"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "68"}, {"groupId": "FG002", "numSubjects": "71"}, {"groupId": "FG003", "numSubjects": "65"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Ineligibility determined", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Full consent withdrawn", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Administrative decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol-specified criteria", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study treatment and were not excluded from analysis due to GCP violations.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "BG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "BG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "BG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "76"}, {"groupId": "BG003", "value": "76"}, {"groupId": "BG004", "value": "302"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.8", "spread": "11.2"}, {"groupId": "BG001", "value": "43.6", "spread": "11.6"}, {"groupId": "BG002", "value": "46.0", "spread": "11.2"}, {"groupId": "BG003", "value": "46.5", "spread": "11.5"}, {"groupId": "BG004", "value": "45.7", "spread": "11.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "46"}, {"groupId": "BG004", "value": "179"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "30"}, {"groupId": "BG004", "value": "123"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "20"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "70"}, {"groupId": "BG003", "value": "73"}, {"groupId": "BG004", "value": "282"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "69"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "67"}, {"groupId": "BG004", "value": "254"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "31"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "10"}]}, {"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Multiple", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "4"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12", "description": "The ACQ is an instrument used in clinical research and practice to evaluate asthma control/impairment.\n\nIt is a validated composite score that assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon awakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and forced expiratory volume in 1 second (FEV1).\n\nThe response options for all these questions range from zero (no impairment/limitation) to six (total impairment/limitation) scale. The total score is obtained by adding the value from each question and dividing by the number of questions. Higher scores indicates worsening of condition and a negative change from baseline indicates improvement.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations, and had non-missing baseline and post-baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "74"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.427", "spread": "0.784"}, {"groupId": "OG001", "value": "-0.521", "spread": "0.796"}, {"groupId": "OG002", "value": "-0.512", "spread": "0.728"}, {"groupId": "OG003", "value": "-0.556", "spread": "0.810"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5838", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.068", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.311", "ciUpperLimit": "0.175"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5391", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.075", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.316", "ciUpperLimit": "0.166"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3583", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.113", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.355", "ciUpperLimit": "0.129"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. FEV1 was performed both pre and post-administration of bronchodilator treatment at Baseline and Week 12.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations, and had non-missing baseline and post-baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters (L)", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "74"}]}], "classes": [{"title": "Pre-Bronchodilator", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "74"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.075", "spread": "0.323"}, {"groupId": "OG001", "value": "0.035", "spread": "0.307"}, {"groupId": "OG002", "value": "0.066", "spread": "0.367"}, {"groupId": "OG003", "value": "0.058", "spread": "0.348"}]}]}, {"title": "Post-Bronchodilator", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "70"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "70"}, {"groupId": "OG003", "value": "67"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.052", "spread": "0.275"}, {"groupId": "OG001", "value": "-0.019", "spread": "0.259"}, {"groupId": "OG002", "value": "0.016", "spread": "0.227"}, {"groupId": "OG003", "value": "-0.032", "spread": "0.285"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Pre-Bronchodilator", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4076", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.047", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.157", "ciUpperLimit": "0.064"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Pre-Bronchodilator", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6915", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.022", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.130", "ciUpperLimit": "0.086"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Pre-Bronchodilator", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7271", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.019", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.126", "ciUpperLimit": "0.088"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Post-Bronchodilator", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9210", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.005", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.086", "ciUpperLimit": "0.095"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Post-Bronchodilator", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1139", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.070", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.017", "ciUpperLimit": "0.157"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Post-Bronchodilator", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6426", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.021", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.066", "ciUpperLimit": "0.107"}]}, {"type": "SECONDARY", "title": "Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR) to Week 12", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations, and had non-missing baseline and post-baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres/minute", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"title": "AM", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.26", "spread": "39.220"}, {"groupId": "OG001", "value": "-14.09", "spread": "46.708"}, {"groupId": "OG002", "value": "-4.53", "spread": "46.468"}, {"groupId": "OG003", "value": "-1.95", "spread": "44.624"}]}]}, {"title": "PM", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "37.807"}, {"groupId": "OG001", "value": "-11.56", "spread": "40.277"}, {"groupId": "OG002", "value": "-9.16", "spread": "45.080"}, {"groupId": "OG003", "value": "-7.96", "spread": "37.984"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "AM", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0262", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-16.847", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.686", "ciUpperLimit": "-2.009"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "AM", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3627", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-6.723", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.239", "ciUpperLimit": "7.793"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "AM", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4507", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-5.488", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.791", "ciUpperLimit": "8.814"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "PM", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1228", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-10.426", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.686", "ciUpperLimit": "2.834"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "PM", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3092", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-6.738", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.758", "ciUpperLimit": "6.281"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "PM", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2167", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-8.043", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.831", "ciUpperLimit": "4.744"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Frequency of Rescue Short Acting \u03b2-Agonist (SABA) Use to Week 12", "description": "Participants recorded SABA use for 1 week prior to randomization (baseline) and the average number of days recorded was subtracted from average days of SABA use across 12 week intervention period.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations, and had non-missing baseline and post-baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.630", "spread": "2.842"}, {"groupId": "OG001", "value": "-0.187", "spread": "2.971"}, {"groupId": "OG002", "value": "-0.727", "spread": "2.941"}, {"groupId": "OG003", "value": "-0.798", "spread": "4.293"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5157", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.331", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.670", "ciUpperLimit": "1.332"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6434", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.234", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.229", "ciUpperLimit": "0.760"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6954", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.199", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.196", "ciUpperLimit": "0.799"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daily Asthma Symptom Score to Week 12", "description": "Participants recorded their daily asthma symptoms in their electronic diaries (Ediary). It included 7 questions: frequency of night time awakening, time awake at night, wheezing, shortness of breath, cough, chest tightness and activity limitation.\n\nDaily asthma symptoms score is the sum of 7 individual scores (with the total score ranging from 0-21).\n\nHigher scores indicates worsening of condition and a negative change from baseline indicates improvement.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations, and had non-missing baseline and post-baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.531", "spread": "3.674"}, {"groupId": "OG001", "value": "-1.816", "spread": "3.250"}, {"groupId": "OG002", "value": "-1.629", "spread": "2.620"}, {"groupId": "OG003", "value": "-1.607", "spread": "3.238"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5577", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.283", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.231", "ciUpperLimit": "0.665"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.9366", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.038", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.904", "ciUpperLimit": "0.980"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.7745", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.138", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.808", "ciUpperLimit": "1.084"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12", "description": "The AQLQ is the most commonly used asthma specific instrument and includes evaluations of both symptom and quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms (Mitchell EA et al, 1997, Juniper et al, 1994, Christie MJ et al, 1993, Juniper et al, 1993).\n\nParticipants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score = mean of the responses to the 32 questions.\n\nHigher scores indicate \"better quality of life\" and a positive change from baseline indicates improved symptoms.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations, and had non-missing baseline and post-baseline data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "69"}, {"groupId": "OG003", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.626", "spread": "0.901"}, {"groupId": "OG001", "value": "0.596", "spread": "0.979"}, {"groupId": "OG002", "value": "0.537", "spread": "0.710"}, {"groupId": "OG003", "value": "0.587", "spread": "0.866"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.8524", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "0.026", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.251", "ciUpperLimit": "0.303"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.8139", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.033", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.305", "ciUpperLimit": "0.240"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.9881", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.002", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.281", "ciUpperLimit": "0.276"}]}, {"type": "SECONDARY", "title": "Proportion of Asthma Symptom-free Days", "description": "Asthma symptom-free days were defined as a participant having a score of zero in their daily asthma symptom score. Asthma symptom-free days without SABA use were defined as a participant having a score of zero in their daily asthma symptom score and no SABA use.\n\nThe proportion of asthma symptom-free days was calculated as the number of asthma symptom-free days over the number of days in the double-blind treatment period (12 weeks).", "populationDescription": "All randomized participants who received at least 1 dose of study treatment who were not excluded due to GCP violations", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Up to Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "76"}, {"groupId": "OG001", "value": "74"}, {"groupId": "OG002", "value": "76"}, {"groupId": "OG003", "value": "76"}]}], "classes": [{"title": "With use of SABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.230", "spread": "0.299"}, {"groupId": "OG001", "value": "0.167", "spread": "0.263"}, {"groupId": "OG002", "value": "0.198", "spread": "0.293"}, {"groupId": "OG003", "value": "0.166", "spread": "0.267"}]}]}, {"title": "Without use of SABA", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.201", "spread": "0.294"}, {"groupId": "OG001", "value": "0.123", "spread": "0.241"}, {"groupId": "OG002", "value": "0.181", "spread": "0.286"}, {"groupId": "OG003", "value": "0.146", "spread": "0.256"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "With use of SABA", "pValue": "0.1213", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.062", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.141", "ciUpperLimit": "0.017"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "With use of SABA", "pValue": "0.6643", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.095", "ciUpperLimit": "0.061"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.2879", "statisticalMethod": "ANCOVA", "statisticalComment": "With use of SABA", "paramType": "LS Mean Difference", "paramValue": "-0.042", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.121", "ciUpperLimit": "0.036"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Without use of SABA", "pValue": "0.0546", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.074", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.150", "ciUpperLimit": "0.001"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Without use of SABA", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9078", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.004", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.080", "ciUpperLimit": "0.071"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Without use of SABA", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3616", "statisticalMethod": "ANCOVA", "paramType": "LS Mean Difference", "paramValue": "-0.035", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.111", "ciUpperLimit": "0.040"}]}, {"type": "SECONDARY", "title": "Time to Maximum Observed Concentration (Tmax) of AMG 827 at Week 8 to 10", "populationDescription": "The pharmacokinetic (PK) analyses set: all participants who received at least one dose of AMG 827 and who had at least 1 PK concentration measurement.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Days", "timeFrame": "Week 8 (days 60 and 64), and pre-dose on Week 10", "groups": [{"id": "OG000", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.1", "lowerLimit": "0.0", "upperLimit": "8.0"}, {"groupId": "OG001", "value": "3.1", "lowerLimit": "0.0", "upperLimit": "9.1"}, {"groupId": "OG002", "value": "3.9", "lowerLimit": "1.9", "upperLimit": "13.0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Observed Concentration (Cmax) of AMG 827 at Week 8 to 10", "populationDescription": "The pharmacokinetic (PK) analyses set: all participants who received at least one dose of AMG 827 and who had at least 1 PK concentration measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "Week 8 (days 60 and 64), and pre-dose on Week 10", "groups": [{"id": "OG000", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.11", "spread": "6.91"}, {"groupId": "OG001", "value": "16.6", "spread": "12.4"}, {"groupId": "OG002", "value": "29.4", "spread": "17.5"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve During the Dosing Interval (AUCtau) of AMG 827 at Week 8 to 10", "populationDescription": "The pharmacokinetic (PK) analyses set: all participants who received at least one dose of AMG 827 and who had at least 1 PK concentration measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5g*day/mL", "timeFrame": "Week 8 (days 60 and 64), and pre-dose on Week 10", "groups": [{"id": "OG000", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG001", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}, {"id": "OG002", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "68.3", "spread": "74.3"}, {"groupId": "OG001", "value": "171", "spread": "150"}, {"groupId": "OG002", "value": "313", "spread": "196"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Day 1 to Week 16", "description": "All-cause mortality is reported for all participants randomized in the study that were not excluded from analysis due to GCP violations. Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug that were not excluded from analysis due to GCP violations.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received the matching placebo administered as a subcutaneous (SC) injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "deathsNumAffected": 0, "deathsNumAtRisk": 77, "seriousNumAffected": 1, "seriousNumAtRisk": 76, "otherNumAffected": 24, "otherNumAtRisk": 76}, {"id": "EG001", "title": "AMG 827 140 mg", "description": "Participants received AMG 827 140 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "deathsNumAffected": 0, "deathsNumAtRisk": 75, "seriousNumAffected": 3, "seriousNumAtRisk": 74, "otherNumAffected": 28, "otherNumAtRisk": 74}, {"id": "EG002", "title": "AMG 827 210 mg", "description": "Participants received AMG 872 210 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "deathsNumAffected": 0, "deathsNumAtRisk": 76, "seriousNumAffected": 1, "seriousNumAtRisk": 76, "otherNumAffected": 28, "otherNumAtRisk": 76}, {"id": "EG003", "title": "AMG 827 280 mg", "description": "Participants received AMG 827 280 mg administered as a SC injection at Day 1 and weeks 1, 2, 4, 6, 8, and 10.", "deathsNumAffected": 0, "deathsNumAtRisk": 77, "seriousNumAffected": 2, "seriousNumAtRisk": 76, "otherNumAffected": 28, "otherNumAtRisk": 76}], "seriousEvents": [{"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}, {"term": "Meningitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}, {"term": "Otitis externa", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 76}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}, {"term": "Hypoglycaemia unawareness", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 76}]}, {"term": "Degeneration of uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}], "otherEvents": [{"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 76}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 76}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 76}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 76}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 76}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 76}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 76}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 76}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "10 participants from 1 site were excluded from all analysis due to major GCP violations."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."}, "pointOfContact": {"title": "Study Director", "organization": "Amgen Inc.", "email": "medinfo@amgen.com", "phone": "866-572-6436"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571216", "term": "Brodalumab"}], "ancestors": [{"id": "D000003879", "term": "Dermatologic Agents"}], "browseLeaves": [{"id": "M279808", "name": "Brodalumab", "asFound": "Irrigation solution", "relevance": "HIGH"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}